Allitinib

Cas No.:	897383-62-9
Chemical Name:	AST-1306
Synonyms:	AST-1306;AST-1306 (tosilate);N-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)acrylamide;N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-Propenamide;N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide;AST 1306;QCR-149;GLXC-15035;HY-15375;J-523015;Allitinib;N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)acrylamide;ALS 1306;CX0M5RO7CY;NCGC00346478-05;AC-32040;EX-A047;BCP05802;BCP9000327;SCHEMBL233985;NCGC00346478-02;GTPL9912;SB19364;AKOS025149073;FT-0768662;N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]quinazolin-6-yl]prop-2-enamide;CS-0983;AST-6;n-(4-((3-chloro-4-((3-fluorophenyl)methoxy)phenyl)amino)-6-quinazolinyl)-2-propenamide;XKB38362;DTXSID30647124;N-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin-6-yl]acrylamide;AST1306;Q27163306;897383-62-9;2-Propenamide, N-(4-((3-chloro-4-((3-fluorophenyl)methoxy)phenyl)amino)-6-quinazolinyl)-;CHEMBL1947204;ALL-3;897383-62-9 (free base);CHEBI:91467;UNII-CX0M5RO7CY;N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide;N-(4-{3-Chloro-4-[(3-fluorophenyl)methoxy]anilino}quinazolin-6-yl)prop-2-enamide;DB-078476;ALS-1306;N-(4-(4-(3-Fluorobenzyloxy)-3-chlorophenylamino)quinazolin-6-yl) Acrylamide;BRD-K26838195-075-04-9;SDCCGSBI-0654468.P001;N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-quinazolinyl)acrylamide;DTXCID10597875;N-(4-(3-Chloro-4-((3-fluorophenyl)methoxy)anilino)quinazolin-6-yl)prop-2-enamide;TS-07958;ALS1306;N-(4-((3-chloro-4-((3-fluorophenyl)methoxy)phenyl)amino)quinazolin-6-yl)prop-2-enamide
SMILES:	FC1=CC=CC(COC2=C(Cl)C=C(NC3=NC=NC4=C3C=C(NC(C=C)=O)C=C4)C=C2)=C1
Formula:	C24H18ClFN4O2
M.Wt:	448.88
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays; also inhibits ErbB4 (IC50=0.8 nM), displays >3,000-fold selectivity over other kinase families; exhibits strong antiproliferative effects on a panel of cancer cell lines, and potently suppresses tumor growth in vivo; orally available.